Stock Price, Quote, News and Profile of ROIVANT SCIENCES LTD(NASDAQ:ROIV) stock

ROIVANT SCIENCES LTD

NASDAQ:ROIV (1/14/2025, 8:03:14 PM)

After market: 10.7206 -0.22 (-2.01%)

10.94

+0.2 (+1.86%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%22.5%

Sales Q2Q%-21.13%

CRS44.1

6 Month-0.55%

Overview

Earnings (Last)11-12 2024-11-12/bmo

Earnings (Next)N/A N/A

Ins Owners7.49%

Inst Owners73.19%

Market Cap7.96B

Shares727.95M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts85

Short Float %8.58%

Short Ratio8.78

IPO12-03 2020-12-03

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; mosliciguat, an inhaled soluble sGC activator in development for pulmonary hypertension associated with interstitial lung disease, in addition to other clinical-stage molecules; and namilumab, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor, an inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.

Company Info

ROIVANT SCIENCES LTD

11-12 St. James's Square, Suite 1, 3rd Floor

London

P: 442074003347.0

Employees: 845

Website: http://roivant.com/

ROIV News

7 days ago - Market News VideoROIV Crosses Below Key Moving Average Level

a month ago - Roivant SciencesRoivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

a month ago - Roivant SciencesKinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis